John P. Butler insider trades: Akebia Therapeutics (AKBA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where John reports to the SEC
Open-market buys and sales
23 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 4, 2026 | AKBA | ↑ Buy | 69,270 | $1.25 | $87K | Direct | Mar 5, 2026 (1d) |
| Feb 2, 2026 | AKBA | ↓ Sell10b5-1 | 341,305 | $1.39 | $474K | Direct | Feb 4, 2026 (2d) |
| Mar 3, 2025 | AKBA | ↓ Sell10b5-1 | 46,409 | $1.83 | $85K | Direct | Mar 4, 2025 (1d) |
| Feb 3, 2025 | AKBA | ↓ Sell10b5-1 | 144,250 | $2.10 | $303K | Direct | Feb 4, 2025 (1d) |
| Feb 29, 2024 | AKBA | ↓ Sell | 46,570 | $1.58 | $74K | Direct | Mar 1, 2024 (1d) |
| Feb 27, 2024 | AKBA | ↓ Sell | 37,733 | $1.52 | $57K | Direct | Feb 29, 2024 (2d) |
| Feb 1, 2024 | AKBA | ↓ Sell | 46,489 | $1.68 | $78K | Direct | Feb 2, 2024 (1d) |
| Jun 14, 2023 | ZYNE | ↓ Sell | 115 | $0.35 | $40 | Direct | Jun 15, 2023 (1d) |
| Mar 1, 2023 | AKBA | ↓ Sell | 91,868 | $0.88 | $81K | Direct | Mar 3, 2023 (2d) |
| Feb 27, 2023 | AKBA | ↓ Sell | 38,632 | $0.81 | $31K | Direct | Mar 1, 2023 (2d) |
| Jun 14, 2022 | ZYNE | ↓ Sell | 53 | $1.01 | $54 | Direct | Jun 16, 2022 (2d) |
| Mar 1, 2022 | AKBA | ↓ Sell | 79,026 | $2.17 | $171K | Direct | Mar 2, 2022 (1d) |
| Apr 1, 2021 | AKBA | ↓ Sell | 4,109 | $3.40 | $14K | Direct | Apr 1, 2021 (0d) |
| Mar 1, 2021 | AKBA | ↓ Sell | 49,990 | $3.40 | $170K | Direct | Mar 2, 2021 (1d) |
| Nov 20, 2019 | AKBA | ↑ Buy | 50,000 | $3.44 | $172K | Direct | Nov 21, 2019 (1d) |
| Aug 22, 2018 | ZYNE | ↑ Buy | 5,000 | $6.43 | $32K | Direct | Aug 22, 2018 (0d) |
| Jun 7, 2016 | RLYP | ↓ Sell | 1,013 | $19.32 | $20K | Direct | Jun 8, 2016 (1d) |
| Jun 11, 2015 | RLYP | ↓ Sell | 1,100 | $34.62 | $38K | Direct | Jun 15, 2015 (4d) |
| Dec 29, 2014 | AKBA | ↑ Buy10b5-1 | 1,000 | $11.57 | $12K | Direct | Dec 29, 2014 (0d) |
| Dec 22, 2014 | AKBA | ↑ Buy10b5-1 | 1,000 | $11.92 | $12K | Direct | Dec 22, 2014 (0d) |
| Dec 15, 2014 | AKBA | ↑ Buy10b5-1 | 1,000 | $11.34 | $11K | Direct | Dec 18, 2014 (3d) |
| Nov 12, 2014 | AKBA | ↑ Buy | 1,000 | $10.30 | $10K | Direct | Nov 13, 2014 (1d) |
| Mar 25, 2014 | AKBA | ↑ Buy | 13,850 | $17.00 | $235K | Direct | Mar 27, 2014 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AKBA insiders
Open-market trades in the last 12 months
About John P. Butler's insider trades
John P. Butler is CEO and President at Akebia Therapeutics (AKBA). Since Mar 25, 2014, John has reported 8 open-market purchases worth $571K and 15 sales worth $1.6M on SEC Form 4. In the last 12 months: 1 buy ($87K) and 1 sale ($474K).
3 sales (54% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include grants and awards (28 filings), option exercises (8 filings), other transactions (2 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AKBA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.